Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization

Area of Science:

• Immunology
• Vaccinology
• Allergy Research

Background:

• Replicase-based DNA vaccines induce T(H)1 immune responses and cell apoptosis, crucial for safe and effective immunotherapy of type I allergies.
• Conventional DNA vaccines require high doses, raising safety concerns for clinical application.

Purpose of the Study:

• To compare the antiallergic potential of a Sindbis virus replicon-based DNA vaccine with a conventional DNA vaccine.
• To evaluate vaccine efficacy in a mouse model of timothy grass pollen allergy.

Main Methods:

• Mice were vaccinated with DNA vaccines encoding Phl p 5 allergen.
• Immune responses, antibody subclasses (IgG1, IgG2a, IgE), and allergic symptoms were assessed.
• In vitro assays measured splenocyte proliferation and cytokine secretion; in vivo analysis included bronchoalveolar lavage and lung pathology.

Main Results:

• Both vaccines promoted T(H)1-biased immunity, suppressed IgE, reduced eosinophilia, and improved lung pathology.
• The replicon DNA vaccine achieved these effects at a 100-fold lower dose than the conventional vaccine.
• Functional IgE suppression and reduced allergic lung inflammation were observed.

Conclusions:

• Replicon-based DNA vaccines exhibit superior immunogenicity, enabling ultralow dose administration.
• Their high safety profile and efficacy make them promising for clinical treatment of type I allergies.
• Eliminates concerns associated with high-dose conventional DNA vaccines.